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Aim. This study was undertaken in order to determine whether anti-inﬂammatory cytokine interleukin-10 is responsible for a
previously described protection against Klebsiella infection mediated by antilipopolysaccharide antibodies. Methods. BALB/c mice
were infected intraperitoneally with a lethal challenge of Klebsiella pneumoniae Caroli. One group was protected with monoclonal
antibodies prior to infection and the second was not. We measured plasma levels of interleukin-10 at diﬀerent time points by
enzyme immunoassay and analyzed the relation between interleukin-10 and proinﬂammatory cytokines interleukin-6 and tumor
necrosis factor-α in order to determine the association of these ratios with the outcome of infection. Major ﬁndings and conclu-
sions. We found diﬀerent pattern of interleukin-10 production in protected mice compared with unprotected ones. The diﬀerence
is greatest 24 hours postinfection. The ratios between IL-10 and proinﬂammatory cytokines conﬁrmed the suppressed proin-
ﬂammatory response in protected animals, especially 24 hours postinfection. Hence the mortality in unprotected mice begins
immediately after we conclude that such cytokine relation and IL-10 production are, at least partially, responsible for the destiny
of infected animals and the outcome of infection.
Copyright © 2006 Tomislav Rukavina et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Klebsiellapneumoniae(Kpneumoniae)istheimportantcause
of community-acquired and nosocomial infections. In spite
of modern antibiotic therapy, some of these infections are
still characterized by high mortality rates [1, 2]. Therefore
various researches have been conducted for the determina-
tion and characterization of possible virulence factors that
are involved in pathogenicity and might serve as target
molecules for the construction of active or passive immuno-
logic tools as an alternative to antibiotic therapy. The promi-
nent morphologic and immunologic feature of Klebsiella spp
is a polysaccharide capsule. Capsular (K) antigen plays a sig-
niﬁcant role in the pathogenicity of Kp n e u m o n i a e[3]a n d
inducesprotectiveimmuneresponse[4].Theobstacleforthe
successful construction of such K antigen-based immuno-
logic tool is the existence of more than 70K antigens on
clinical isolates. Therefore, a more eﬀective Klebsiella vaccine
should probably contain some other surface determinants
with less complex seroepidemiology than that of the K anti-
gen. Lipopolysaccharide (LPS; O antigen) is another promis-
ing candidate surface molecule for the development of such
immunologic tool since there are evidences that antibodies
directed against LPS are capable to penetrate through bac-
terial capsule [5, 6]a n da r ep r o t e c t i v ei nam o u s em o d e lo f
lethal systemic Klebsiella infection [7]. Further, the number
of O antigens is relatively low compared to the number of
K antigens. Several seroepidemiological studies have shown
that a great proportion of all Klebsiella clinical isolates be-
longs to only few O antigenic groups [8, 9].
We have previously described an O1 antigen-speciﬁc
murine monoclonal antibody (clone Ru-O1, immunoglob-
ulin G2b; IgG2b) that exerted protection in a murine model
of lethal systemic Klebsiella infection [7]. The exact mecha-
nisms involved in this protection remained unknown. A part
of its protective eﬀect could be contributed to the ability of
coating the encapsulated bacteria which was demonstrated
by in vitro experiments [10]. Besides that, it may also exert
protection by several other mechanisms. One of the possible
mechanisms is neutralization of circulating free LPS and its
biological eﬀects. Cytokines themselves play the important
roleinthepathogenesisofKlebsiellaandothergram-negative
infections. Their production is partly induced by LPS. The
data regarding the role of some cytokines in the pathogenesis
of infections are often controversial [11]. In a previous study
we analyzed the involvement of proinﬂammatory cytokines2 Mediators of Inﬂammation
in the protection of mice against lethal Klebsiella challenge.
We found that animals protected with anti-LPS MAb had
lower concentrations of all cytokines analyzed, especially 24
hours aftertheinfection[12].We concludedthatsuchproin-
ﬂammatory cytokine pattern is important for the outcome
of infection. Cytokine network consists of both, pro- and
anti-inﬂammatory cytokines. Interleukin-10 (IL-10) func-
tions as an anti-inﬂammatory cytokine that suppresses pro-
duction of certain proinﬂammatory mediators [13–15]a n d
exerted anti-inﬂammatory properties in experimental mod-
els of LPS-induced lethality [16, 17]. Moreover, the relation
between IL-10 and some proinﬂammatory cytokines seems
to be important for the outcome of infection [18, 19].
Therefore, in the present study, we tried to determine
whether the protective eﬀect of anti-LPS Ru-O1 MAb could
be a consequence of modulated IL-10 production. We ana-
lyzed plasma concentrations at diﬀerent time points after a
lethal intraperitoneal (IP) bacterial challenge with Kp n e u -
moniae Caroli (O1 : K2). We also evaluated the balance be-
tween IL-10 and certain proinﬂammatory cytokines which
were reported to be important and even predictable for the
outcome of infection at the same time points.
MATERIALS AND METHODS
Animals
Eight- to ten-week-old pathogen-free male BALB/c mice
weighing 20 to 25 grams each were used through study. An-
imals were obtained from the breeding colony at the Med-
ical Faculty, University of Rijeka. They were kept in plastic
cages and given standard laboratory food (standard pellets,
Faculty of Biotechnology, Domˇ zale, Slovenia) and water ad
libitum. The experiments were conducted according to the
laws and principles found in the International Guiding Prin-
ciplesofBiomedicalResearchInvolvingAnimalsbytheCouncil
of International Organisations of Medical Science. The prin-
ciples are also in accordance with the Statute for Laboratory
Animals of the Croatian Society for Laboratory Animals.
Bacteria
Experimentalinfectionswereperformedusingthehighlyvir-
ulent variant of the strain Kp n e u m o n i a eCaroli (O1 : K2)
which has been used before by us [7, 12] and by other au-
thors as well [4].
ExperimentalKlebsiellainfection
The bacterial suspensions were prepared as described previ-
ously [7] .T h ee x p e r i m e n t a lg r o u p so fm i c ew e r ep r e t r e a t e d
four hours before the infection with an IP injection of puri-
ﬁedMAbRu-O1(protectedgroup)atthedoseof40μg/gthat
was determined to be protective, or with PBS (unprotected
group). Animals were injected IP with an estimated dose of
50 organisms of Kp n e u m o n i a eCaroli, corresponding to ﬁve
times the LD50. According to our previous ﬁndings, all an-
imals from unprotected group died within 4 days, with the
mortality of approximately 50% after 2 days. Pretreatment
with MAb Ru-O1 resulted in 70 percent survival.
Plasmacytokineanalysis
The animals were euthanized by inhalation of CO2 and the
blood was obtained immediately after by cardiac puncture
at 2, 6, 12, and 24 hours postinfection. Plasma samples were
separated and stored at −20◦C until assayed. Plasma levels
of IL-10 were determined by commercially available mouse
cytokine ELISA kit (Bender MedSystems, Austria) according
to the manufacturer’s instructions. According to data sup-
plied by the manufacturer, detection limit for speciﬁed kit
was 14.52pg/mL. The overall intra-assay and interassay re-
producibilities,expressedbycoeﬃcientofvariation,werede-
clared to be < 5% and < 10%, respectively. The results are
presented as mean values ± SE of the mean (SEM) of cy-
tokine concentration.
DeterminationofIL-10versusproinﬂammatory
cytokineratios
Ratios between IL-10 and proinﬂammatory cytokines
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)
were calculated from absolute values of IL-10 concentrations
obtained in this study and from results for the mentioned
proinﬂammatorycytokinesreportedinapreviousarticleob-
tained from plasma samples of the same experimental ani-
mals [12]. We calculated IL-6/IL-10 and IL-10/TNF-α ratios.
The plasma concentrations of IL-6 in experimental animals
were in range from 0.3t o1 4 .7ng/mLforunprotectedgroup
and from 0.1t o2 .3ng/mL for protected animals. The val-
ues of TNF-α ranged from 0.5t o3 .2ng/mLforunprotected
group and from 0.1t o1 .1ng/mL for the protected group.
Statisticalanalysis
Statistical signiﬁcance of the diﬀerence between cytokine
concentrations of unprotected, protected, and uninfected
control groups was determined by two-tailed Student t test.
RESULTS
KineticsofIL-10concentration
Two hours after the infection, IL-10 concentration in both
experimental groups increased above the level in uninfected
control animals (Figure 1). After six hours, the concentra-
tion in unprotected group further increased while the con-
centration in protected animals remained almost unchanged
(1389 ± 137 versus 971 ± 101pg/mL; NS). Twelve hours
postinfection concentrations in both infected groups in-
creased almost to the same level, reaching the maximum in
unprotected animals (1683 ± 109pg/mL). During the next
twelve hours, IL-10 concentration continues to increase in
theprotectedgroup(2230±253pg/mL)whileinunprotected
animals the concentration decreases to the level of 1314 ±
111pg/mL (P<. 02).Tomislav Rukavina et al 3
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Figure 1: Plasma concentration of IL-10 in the blood of BALB/c
mice protected with anti-LPS MAb Ru-O1 (gray bars) and unpro-
tected mice (white bars) after the IP infection with 50 CFU of K
pneumoniae Caroli (O1 : K2) at diﬀerent time points. Results are
expressed as mean values ± SEM ng/mL. Six animals in each group
were infected. ∗Above bars represents the statistical signiﬁcance be-
tween the groups at the level of P<. 02. Horizontal line represents
the mean value of plasma IL-10 concentration in the blood of un-
infected control mice.
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Figure 2: IL-6/IL-10 ratio in BALB/c mice protected with anti-LPS
MAb Ru-O1 (gray bars) and unprotected mice (white bars) after
the IP infection with 50 CFU of K pneumoniae Caroli (O1 : K2) at
diﬀerent time points.
IL-6/IL-10ratio
Two, six, and twelve hours after the infection, IL-6/IL-10 ra-
tio remained lower than 1 in unprotected group (Figure 2).
Twenty four hours postinfection, the value dramatically in-
creased to the level of 11.2. In the protected group, the ra-
tio was lower compared to unprotected animals at all time
points except 6 hours after the infection when it reached the
highest value of 2.4. The most prominent diﬀerence between
two groups was 24 hours postinfection, when in protected
animalstheratiovaluewasapproximately19-foldlowerthan
that in unprotected group.
IL-10/TNF-αratio
IL-10/TNF-αratio(Figure 3)inunprotectedgroupremained
at all time points within the range from 0.4 (12 hours postin-
fection) to 1.6 (2 hours postinfection). In the protected
group, the ratio was the highest two hours after the infection
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Figure 3: IL-10/TNF-α ratio in BALB/c mice protected with anti-
LPS MAb Ru-O1 (gray bars) and unprotected mice (white bars) af-
ter the IP infection with 50 CFU of K pneumoniae Caroli (O1 : K2)
at diﬀerent time points.
(6.8) and then markedly decreased to the value of 2 (6 hours
postinfection). Theﬁnalratiovalueinthisgroupreachedthe
level of 4.4. This value is 11-fold higher than that in the un-
protected group.
DISCUSSION
We have previously reported that anti-LPS MAb Ru-O1 ex-
e r t e dp r o t e c t i o ni nam u r i n em o d e lo fl e t h a ls y s t e m i cKleb-
siella infection [7]. In a previous article, we reported that
this eﬀect can partially be explained by modulation of proin-
ﬂammatory cytokine response [12]. Since the production of
proinﬂammatory cytokines during the course of infection
canbeharmfulandmayleadtoshock,multiple-organfailure
and death [20, 21], anti-inﬂammatory cytokines such as IL-
10 are necessary for downregulating inﬂammatory process
and maintaining homeostasis for proper function of vital or-
gans [16, 22].
We have also reported that after the IP challenge, accord-
ing to our experimental design, bacteria appear in blood two
and six hours after the infection in unprotected and pro-
tected groups, respectively [12]. The results of the present
study suggest that the kinetics of IL-10 production depends
also on the beginning of bacteremia. After the initial rise
in plasma IL-10 concentration (2 hours postinfection) that
was detected in both groups compared to uninfected ani-
mals, in unprotected group the concentration continues to
increase reaching its maximum 12 hours postinfection. On
the contrary, in the protected group IL-10 concentration be-
gins to increase later (between 6 and 12 hours) and contin-
ues to increase until 24 hours of infection. Elevated concen-
tration in this group remained at almost unchanged level
during the next 24 hours and then slightly begun to de-
crease (data not shown). We presumed that the degree of
bacteremia correlates with a quantity of liberated bacterial
compounds including LPS. Our presumption is that the
quantity of circulating LPS and its eﬀects are diminished in
the protected group because of its binding to MAb. We also
presumed that a part of MAb has coated the circulating bac-
teria resulting in activation of other available defense mecha-
nisms. These events may result in diﬀerent IL-10 production4 Mediators of Inﬂammation
patterns between groups. We speculate that the dynamic of
greater IL-10 production in unprotected animals during the
early phase is responsible for inadequate inﬂammatory re-
action and control of infectious agent. On the other hand,
anti-inﬂammatory cytokine response in protected animals
was lower during the ﬁrst six hours. Such condition may be
responsible for the development of more eﬀective inﬂamma-
tion and better control of infectious agent during that phase.
LPS is known to be a stimulator of IL-10 production
and IL-10 was described to exert beneﬁcial eﬀects in sev-
eral experimental models [16, 23]. Our results partially sup-
port such ﬁndings. IL-10 level in our experiment was dif-
ferent between two groups especially 24 hours postinfection
with higher concentration in the protected group. Hence
the mortality in unprotected group begins immediately af-
ter we concluded that the cytokine proﬁle at this stage is
important for the outcome of infection. We speculate that
higher IL-10 concentration in the protected group 24 hours
postinfection eﬃciently downregulates the production of
proinﬂammatory cytokines which we analyzed previously
[12]. The highest level of IL-10 in unprotected group was
detected after 12 hours. At this time point, proinﬂamma-
tory cytokines production started to exceed the production
of IL-10. We presumed that the excessive proinﬂammatory
production, especially 24 hours postinfection, could not be
counteracted by anti-inﬂammatory eﬀect of IL-10 and other
anti-inﬂammatory cytokines. Therefore, we speculate that
such cytokine pattern expressed deleterious eﬀects that con-
tributed mortality.
Several clinical studies reported that high anti-inﬂam-
matory cytokine levels at certain stages of infection are as-
sociated with the poor outcome of infection [18, 19]. On the
contrary, the association of high IL-10 level with increased
mortality was not conﬁrmed in laboratory models of sep-
sis since exogenous administration of IL-10 conferred pro-
tection against excessive proinﬂammatory cytokine produc-
tion and mortality [16, 22, 24]. Our results support these
experimental data. Possible explanation for such diﬀerence
between mentioned clinical and experimental results may be
the statement that IL-10 eﬀect depends on timing, dose, and
location of expression [25]. These parameters could be con-
trolled and followed in experimental conditions only, so the
comparison with infected patients’ data is sometimes diﬃ-
cult or impossible.
Further,diﬀerentstudiessuggestedtheimportanceofthe
balance between anti- and proinﬂammatory cytokines for
the outcome of systemic infection. To date, the interaction
between these cytokine groups in response to sepsis remains
a controversial subject. Proinﬂammatory cytokines IL-6 and
TNF-α are capable to induce a strong inﬂammatory reac-
tion that may lead to severe hypotension, multiple-organ
dysfunction, and death [26, 27]. Such response ultimately
triggers a compensatory anti-inﬂammatory reaction involv-
ing antagonist mediators including IL-10. IL-10 has the abil-
ity to suppress the synthesis of proinﬂammatory cytokines
and eﬀectively downregulates the proinﬂammatory reaction
[14, 28]. However, the highest values of the IL-10/TNF-α ra-
tio were reported to be associated with the poor outcome in
sepsis [18] and in febrile hospitalized patients [19]. Our re-
sults are in contrast with such ﬁndings since the IL-10/TNF-
α ratio is higher in surviving protected animals, especially 24
hours postinfection. On the contrary, our experimental re-
sults are in accordance with results of several studies that re-
ported the correlation of high IL-6/IL-10 ratio and the poor
outcome in patients with systemic inﬂammation [29, 30].
Such ﬁndings can probably be explained by the exaggerated
proinﬂammatory response that is associated with inadequate
anti-inﬂammatory compensation [30].
Theexactmechanismsinvolvedindiﬀerentcytokinepro-
d u c t i o np a t t e r n sb e t w e e nt w og r o u p si no u re x p e r i m e n t sr e -
quire more detailed studies. They should certainly consider
the fact that the main diﬀerence between these groups is the
presence of anti-O1 MAb of the IgG2b subclass in the pro-
tected group. LPS molecule itself is known to activate sur-
face receptors on the cells of innate immune system result-
ing in activation of series of signaling events that potentiate
the production of molecular mediators. Ru-O1 MAb by its
binding to circulating LPS most probably reduces the level of
LPS interaction with the endotoxin sensing apparatus, lead-
ing to modiﬁed cytokine production in protected animals.
On the other hand, Fc fragment of IgG in immune com-
plexes was described to be involved in upregulation of IL-
10 production through its binding to Fc receptors [31]. We
presume that such upregulation is present in protected an-
imals. However, modiﬁed IL-10 production with beneﬁcial
eﬀects in protected animals may also be the consequence of
someotherregulatorymechanismsinvolved.Severalrecently
published articles suggested the close cooperation between
innate and adaptive immune responses [32, 33]. We believe
that in our experimental model, this cooperation of MAbs as
eﬀector molecules of the adaptive immune response with the
innate immune response to LPS is possible, but this hypoth-
esis requires conﬁrmation by future research.
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